Identification
- Summary
Sodium phosphate, monobasic is a source of phosphorus used prevent or correct hypophosphatemia in patients with restricted or no oral intake.
- Brand Names
- As 3, Cpda-1 Blood Collection System, Glycerolyte 57, Intersol, Ionosol-MB, K-phos Neutral, K-phos No 2, Leukotrap, Osmoprep, Phosphasal, Rejuvesol, Urelle, Uribel, Urimar Reformulated Oct 2013, Urin DS, Ustell
- Generic Name
- Sodium phosphate, monobasic
- DrugBank Accession Number
- DB09449
- Background
Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Sodium phosphate, monobasic (DB09449)
- Weight
- Average: 119.977
Monoisotopic: 119.958839739 - Chemical Formula
- H2NaO4P
- Synonyms
- Disodium hydrogen phosphate anhydrous
- Monosodium dihydrogen monophosphate
- Monosodium dihydrogen orthophosphate
- Monosodium monophosphate
- Monosodium phosphate, anhydrous
- Phosphoric acid, monosodium salt, anhydrous
- Sodium acid phosphate
- Sodium biphosphate, anhydrous
- Sodium dihydrogen phosphate
- Sodium dihydrogen phosphate, anhydrous
- Sodium orthophosphate
- Sodium orthophosphate monobasic
- Sodium phosphate monobasic
- Sodium phosphate monobasic (anhydrate)
- Sodium phosphate monobasic (anhydrous)
- Sodium phosphate, monobasic
- Sodium phosphate, monobasic anhydrous
- Sodium phosphate,monobasic
- Sodium primary phosphate
- External IDs
- E-339(I)
- INS NO.339(I)
- INS-339(I)
Pharmacology
- Indication
Used to treat constipation or to clean the bowel before a colonoscopy Label.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Associated Therapies
- Bowel preparation therapy
- Continuous Renal Replacement Therapy
- Electrolyte replacement
- Fluid replacement therapy
- Parenteral Nutrition
- Parenteral rehydration therapy
- Total parenteral nutrition therapy
- Fluid and electrolyte maintenance therapy
- Irrigation of the ocular surface therapy
- Red blood cell rejuvination therapy
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Sodium phosphate inceases fecal water content to increase mobility through the large intestine 1.
- Mechanism of action
Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen 1.
- Absorption
Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h 3.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats 7. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma 4. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients 3.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol Sodium phosphate, monobasic may increase the hyperkalemic activities of Acebutolol. Aceclofenac The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Aceclofenac. Acemetacin The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Acemetacin. Acetazolamide Acetazolamide may increase the nephrotoxic activities of Sodium phosphate, monobasic. Acetylsalicylic acid The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Acetylsalicylic acid. Aclidinium The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Aclidinium. Alclofenac The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Alclofenac. Alfentanil The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Alfentanil. Aliskiren The risk or severity of nephrotoxicity can be increased when Aliskiren is combined with Sodium phosphate, monobasic. Alloin The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Alloin. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Sodium phosphate, monobasic, dihydrate 5QWK665956 13472-35-0 VBJGJHBYWREJQD-UHFFFAOYSA-M Sodium phosphate, monobasic, monohydrate 593YOG76RN 10049-21-5 BBMHARZCALWXSL-UHFFFAOYSA-M - Active Moieties
Name Kind UNII CAS InChI Key Phosphoric acid unknown E4GA8884NN 7664-38-2 NBIIXXVUZAFLBC-UHFFFAOYSA-N Sodium cation ionic LYR4M0NH37 17341-25-2 FKNQFGJONOIPTF-UHFFFAOYSA-N Phosphate ion ionic NK08V8K8HR 14265-44-2 NBIIXXVUZAFLBC-UHFFFAOYSA-K - Product Images
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Additive Formula 3 Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) Solution Intravenous Terumo Bct, Ltd 2002-05-29 Not applicable US 
Additive Formula 3 Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) Solution Intravenous Terumo Bct, Ltd 2002-05-29 Not applicable US Additive Formula 3 Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) Solution Intravenous Terumo Bct, Ltd 2002-05-29 Not applicable US Additive Formula 3 Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) Solution Intravenous Terumo Bct, Ltd 2002-05-29 Not applicable US Additive Formula 3 Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) Solution Intravenous Terumo Bct, Ltd 2002-05-29 Not applicable US Additive Formula 3 Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) Solution Intravenous Terumo Bct, Ltd 2002-05-29 Not applicable US Additive Solution Formula 3 As-3 Sodium phosphate, monobasic, monohydrate (0.276 g) + Adenine (0.030 g) + Citric acid monohydrate (0.042 g) + Dextrose, unspecified form (1.10 g) + Sodium chloride (0.410 g) + Sodium citrate dihydrate (0.588 g) Solution Extracorporeal Terumo Bct, Inc. 2013-05-31 Not applicable Canada 
Adsol Red Cell Preservation Sodium phosphate, monobasic, dihydrate (176 mg/70mL) + Adenine (30 mg/110mL) + Citric acid (229 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) Kit; Solution Intravenous Fenwal, Inc. 2022-06-10 Not applicable US Adsol Red Cell Preservation Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) Kit Intravenous Fenwal, Inc. 2017-02-28 Not applicable US Adsol Red Cell Preservation Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) Kit; Solution Intravenous Fenwal, Inc. 2021-12-09 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Azuphen Mb Sodium phosphate, monobasic, monohydrate (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (120 mg/1) + Methylene blue trihydrate (10 mg/1) + Phenyl salicylate (36 mg/1) Capsule Oral Burel Pharmaceuticals, Llc 2015-09-28 2016-11-01 US B.T.ENEMA 135 ML SOLUSYON Sodium phosphate, monobasic (135 ml) Solution Rectal YENİŞEHİR LABORATUARI LTD. ŞTİ. 2020-08-14 2022-04-11 Turkey 
B.T.ENEMA 210 ML LAVMAN Sodium phosphate, monobasic (9.5 g/59ml) + Sodium phosphate, dibasic (3.5 g/59ml) Enema Rectal YENİŞEHİR LABORATUARI LTD. ŞTİ. 2020-08-14 2022-04-11 Turkey B.T.ENEMA 67,5 ML LAVMAN Sodium phosphate, monobasic (9.5 g/59ml) + Sodium phosphate, dibasic (3.5 g/59ml) Enema Rectal YENİŞEHİR LABORATUARI LTD. ŞTİ. 2020-08-14 2022-04-11 Turkey BT ORAL SOLUSYON 45 ML Sodium phosphate, monobasic (45 ml) Solution Oral YENİŞEHİR LABORATUARI LTD. ŞTİ. 2020-08-14 Not applicable Turkey Darpaz Sodium phosphate, monobasic (40.8 mg/1) + Hyoscyamine sulfate dihydrate (.12 mg/1) + Methenamine (81 mg/1) + Methylene blue trihydrate (10.8 mg/1) + Phenyl salicylate (32.4 mg/1) Tablet Oral River's Edge Pharmaceuticals, LLC 2008-12-01 2011-05-31 US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1) Tablet Oral Avera McKennan Hospital 2015-03-11 2017-05-24 US 
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1) Tablet Oral Cardinal Health 2012-06-28 2018-03-31 US 
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1) Tablet Oral Rising Pharmaceuticals, Inc. 2012-06-28 Not applicable US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1) Tablet Oral Carilion Materials Management 2012-06-28 Not applicable US 
Categories
- ATC Codes
- A06AG01 — Sodium phosphate
- A06AG — Enemas
- A06A — DRUGS FOR CONSTIPATION
- A06 — DRUGS FOR CONSTIPATION
- A — ALIMENTARY TRACT AND METABOLISM
- V03AG — Drugs for treatment of hypercalcemia
- V03A — ALL OTHER THERAPEUTIC PRODUCTS
- V03 — ALL OTHER THERAPEUTIC PRODUCTS
- V — VARIOUS
- A06AD — Osmotically acting laxatives
- A06A — DRUGS FOR CONSTIPATION
- A06 — DRUGS FOR CONSTIPATION
- A — ALIMENTARY TRACT AND METABOLISM
- Drug Categories
- Acids
- Acids, Noncarboxylic
- Agents that reduce seizure threshold
- Alimentary Tract and Metabolism
- Anions
- Blood and Blood Forming Organs
- Blood Substitutes and Perfusion Solutions
- Drugs for Constipation
- Drugs for Treatment of Hypercalcemia
- Electrolyte Solutions
- Electrolytes
- Enemas
- I.V. Solution Additives
- Ions
- Laxatives
- Osmotic Laxatives
- Phosphate salts
- Phosphoric Acids
- Phosphorus Acids
- Phosphorus Compounds
- Potassium Salt
- Urinary Acidifying Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkali metal oxoanionic compounds
- Sub Class
- Alkali metal phosphates
- Direct Parent
- Alkali metal phosphates
- Alternative Parents
- Inorganic sodium salts / Inorganic oxides
- Substituents
- Alkali metal phosphate / Inorganic oxide / Inorganic salt / Inorganic sodium salt
- Molecular Framework
- Not Available
- External Descriptors
- sodium phosphate (CHEBI:37585)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- KH7I04HPUU
- CAS number
- 7558-80-7
- InChI Key
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M
- InChI
- InChI=1S/Na.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1
- IUPAC Name
- sodium dihydrogen phosphate
- SMILES
- [Na+].OP(O)([O-])=O
References
- General References
- Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24. [Article]
- Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521. [Article]
- Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27. [Article]
- Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377. [Article]
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- FDA Guide: Sodium Phosphate Tablet [Link]
- ChemIDPlus: Sodium Phosphate [Link]
- External Links
- PubChem Compound
- 23672064
- PubChem Substance
- 347827853
- ChemSpider
- 22626
- ChEBI
- 37585
- ChEMBL
- CHEMBL1368
- Wikipedia
- Sodium_phosphates
- FDA label
- Download (359 KB)
- MSDS
- Download (84.7 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Not Available Dry Eyes 1 4 Completed Diagnostic Colonoscopy 1 4 Completed Diagnostic Polyethylene Glycol / Sodium Phosphate 1 4 Completed Other Sickle Cell Disease (SCD) 1 4 Completed Treatment Cathartic Colon 1 4 Completed Treatment Colon Cleansing 1 4 Completed Treatment Colonoscopy 2 4 Completed Treatment Obstructive Sleep Apnea (OSA) / Psoriasis 1 4 Recruiting Treatment Bleeding / Pain / Post Operative Nausea and Vomiting (PONV) / Tonsillectomy 1 4 Recruiting Treatment Colorectal Neoplasms / Surgery 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Kit; solution Intravenous Injection Intravenous 0.5 g/l Injection Intravenous 0.25 g/1000ml Solution Rectal 135 ml Solution Oral 45 ml Solution Oral 90 ml Solution, concentrate Rectal Liquid Intravenous Kit Intravenous Paste Dental Injection Intrathecal Solution Parenteral Solution Rectal Liquid Irrigation Solution Rectal 133 ml Solution Rectal 66.6 ml Solution Rectal 90 ml Suppository Parenteral Solution Unknown Liquid Intravesical Injection, solution Intravenous Tablet, coated Oral Solution Intravenous 0.775 g Emulsion Parenteral Emulsion Intravenous Injection, emulsion Intravenous 4.656 g/1000ml Injection, emulsion Intravenous 6.792 g/1000ml Injection, emulsion Intravenous Tablet Oral Capsule Oral Solution Oral Liquid Oral Solution Oral 1.2 g/5ml Solution Extracorporeal Solution Rectal 16 %/6% Solution Rectal Enema Rectal Solution Respiratory (inhalation) Injection, solution, concentrate Intravenous Solution Intravenous Solution Oral 0.9 g/5ml Tablet, film coated Oral Tablet, sugar coated Oral Syrup Enema Solution - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US7687075 No 2010-03-30 2028-06-22 US US7084130 No 2006-08-01 2021-11-29 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) Decomposes at 75 MSDS water solubility 121 g/L MSDS - Predicted Properties
Property Value Source logP -1 Chemaxon pKa (Strongest Acidic) 1.8 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 80.59 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 13.53 m3·mol-1 Chemaxon Polarizability 5.53 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Not Available
- Specific Function
- Not Available
- Gene Name
- SLC20A1
- Uniprot ID
- Q8WUM9
- Uniprot Name
- Sodium-dependent phosphate transporter 1
- Molecular Weight
- 73699.01 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Virus receptor activity
- Specific Function
- Sodium-phosphate symporter which seems to play a fundamental housekeeping role in phosphate transport by absorbing phosphate from interstitial fluid for normal cellular functions such as cellular m...
- Gene Name
- SLC20A2
- Uniprot ID
- Q08357
- Uniprot Name
- Sodium-dependent phosphate transporter 2
- Molecular Weight
- 70391.755 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Sodium:phosphate symporter activity
- Specific Function
- Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 70-80% of the apical influx.
- Gene Name
- SLC34A1
- Uniprot ID
- Q06495
- Uniprot Name
- Sodium-dependent phosphate transport protein 2A
- Molecular Weight
- 68936.53 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Sodium:phosphate symporter activity
- Specific Function
- May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the s...
- Gene Name
- SLC34A2
- Uniprot ID
- O95436
- Uniprot Name
- Sodium-dependent phosphate transport protein 2B
- Molecular Weight
- 75758.535 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Sodium:phosphate symporter activity
- Specific Function
- May be involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 20-30% of the apical influx.
- Gene Name
- SLC34A3
- Uniprot ID
- Q8N130
- Uniprot Name
- Sodium-dependent phosphate transport protein 2C
- Molecular Weight
- 63548.94 Da
References
- Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [Article]
Drug created at November 30, 2015 19:10 / Updated at February 13, 2021 10:51